# A Novel Drug for Borderline Personality Disorder

> **NCT02097706** · PHASE2 · RECRUITING · sponsor: **The Alfred** · enrollment: 150 (estimated)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** NMDA receptor antagonist (active drug)
- **OTHER:** Lactose packed capsule (inert/inactive arm)

## Key facts

- **NCT ID:** NCT02097706
- **Lead sponsor:** The Alfred
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-01
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097706, "A Novel Drug for Borderline Personality Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02097706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*